6 results on '"Lauren Pinter-Brown"'
Search Results
2. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network
- Author
-
Won Kim, Luigi Marcheselli, Tatyana Feldman, Lauren Pinter-Brown, Ranjana H. Advani, Marc Schwartz, Andrei R. Shustov, Michele Spina, Young-Hyeh Ko, Kenneth R. Carson, Massimo Federico, Frederick Lansigan, Sonali M. Smith, Maria Elena Cabrera, Stefano Pileri, Silvia Montoto, Steven M. Horwitz, Arnon Nagler, Martina Manni, Vittoria Tarantino, Mary Jo Lechowicz, Monica Bellei, Raul Gabus, Francine M. Foss, and Julie M. Vose
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,T cell ,Peripheral T-cell lymphoma not otherwise specified ,Models, Biological ,survival ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,medicine ,Humans ,risk factors ,Stage (cooking) ,Aged ,Aged, 80 and over ,Hematology ,Performance status ,Haematological Malignancy ,business.industry ,prognostic index ,Lymphoma, T-Cell, Peripheral ,PTCL-NOS ,PTCL‐NOS ,Middle Aged ,medicine.disease ,Confidence interval ,clinical variables ,3. Good health ,Survival Rate ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Absolute neutrophil count ,Female ,business ,Research Paper ,Follow-Up Studies ,030215 immunology ,Ptcl nos - Abstract
Summary Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL‐NOS) have been developed by means of retrospective analyses. Here we report on a new model designed on data from the prospective T Cell Project. Twelve covariates collected by the T Cell Project were analysed and a new model (T cell score), based on four covariates (serum albumin, performance status, stage and absolute neutrophil count) that maintained their prognostic value in multiple Cox proportional hazards regression analysis was proposed. Among patients registered in the T Cell Project, 311 PTCL‐NOS were retained for study. At a median follow‐up of 46 months, the median overall survival (OS) and progression‐free survival (PFS) was 20 and 10 months, respectively. Three groups were identified at low risk (LR, 48 patients, 15%, score 0), intermediate risk (IR, 189 patients, 61%, score 1–2), and high risk (HiR, 74 patients, 24%, score 3–4), having a 3‐year OS of 76% [95% confidence interval 61–88], 43% [35–51], and 11% [4–21], respectively (P
- Published
- 2018
3. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial
- Author
-
Stephen M. Ansell, Barbara Pro, Andrew M. Evens, Kenneth R. Carson, Kerry J. Savage, Lauren Pinter-Brown, Ranjana H. Advani, Francine M. Foss, Steven M. Horwitz, Sonali M. Smith, Julie M. Vose, Anne W. Beaven, Andrei R. Shustov, Fausto R. Loberiza, and Mary Jo Lechowicz
- Subjects
Adult ,Male ,0301 basic medicine ,Vincristine ,medicine.medical_specialty ,medicine.medical_treatment ,Kaplan-Meier Estimate ,CHOP ,Gastroenterology ,Article ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cyclophosphamide ,Etoposide ,Aged ,Epirubicin ,Aged, 80 and over ,Chemotherapy ,business.industry ,Lymphoma, T-Cell, Peripheral ,Pralatrexate ,Hematology ,Middle Aged ,medicine.disease ,Aminopterin ,Surgery ,Transplantation ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Disease Progression ,Prednisone ,Female ,business ,Febrile neutropenia ,medicine.drug - Abstract
Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti-folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL, provided a rationale to incorporate it into the front-line setting. This phase 2 study evaluated a novel front-line combination whereby cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternated with pralatrexate (CEOP-P) in PTCL. Patients achieving a complete or partial remission (CR/PR) were eligible for consolidative stem cell transplantation (SCT) after 4 cycles. Thirty-three stage II-IV PTCL patients were treated: 21 PTCL-not otherwise specified (64%), 8 angioimmunoblastic T cell lymphoma (24%) and 4 anaplastic large cell lymphoma (12%). The majority (61%) had stage IV disease and 46% were International Prognostic Index high/intermediate or high risk. Grade 3-4 toxicities included anaemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), increased creatinine (12%) and liver transaminases (12%). Seventeen patients (52%) achieved a CR. The 2-year progression-free survival and overall survival, were 39% (95% confidence interval 21-57) and 60% (95% confidence interval 39-76), respectively. Fifteen patients (45%) (12 CR) received SCT and all remained in CR at a median follow-up of 21·5 months. CEOP-P did not improve outcomes compared to historical data using CHOP. Defining optimal front line therapy in PTCL continues to be a challenge and an unmet need.
- Published
- 2015
4. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- Author
-
Eric L. Sievers, Nancy L. Bartlett, Ajay K. Gopal, Andres Forero-Torres, André Bosly, Anas Younes, Dana A. Kennedy, Lauren Pinter-Brown, Pauline Brice, John P. Leonard, and Joseph D. Rosenblatt
- Subjects
Adult ,Male ,medicine.medical_specialty ,CD30 ,medicine.medical_treatment ,Phases of clinical research ,Antineoplastic Agents ,Gastroenterology ,Young Adult ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Anaplastic lymphoma kinase ,Anaplastic large-cell lymphoma ,Aged ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Large cell ,Chimerin Proteins ,Large-cell lymphoma ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Antibodies, Anti-Idiotypic ,Lymphoma ,Immunology ,Lymphoma, Large-Cell, Anaplastic ,Female ,business - Abstract
P>SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study to determine the safety and objective response rate of SGN-30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN-30 comprised 6 weekly intravenous infusions, followed by a 2-week treatment-free period. Patients had received a median of 3 (range 1-5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62-242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN-30 is safe, with modest clinical activity in patients with ALCL.
- Published
- 2009
5. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B
- Author
-
Lauren Pinter-Brown, Sugantha Govindarajan, Eddie Hu, Paul C. Pinto, and Marjorie Bernstein-Singer
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lymphoma ,medicine.drug_class ,medicine.medical_treatment ,medicine.disease_cause ,Gastroenterology ,Liver Function Tests ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Hepatitis B virus ,Chemotherapy ,Hepatitis B Surface Antigens ,business.industry ,Lymphoma, Non-Hodgkin ,Immunosuppression ,Middle Aged ,Hepatitis B ,medicine.disease ,Hodgkin Disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Pathophysiology ,Liver ,Oncology ,Chronic Disease ,Immunology ,Prednisone ,Corticosteroid ,Female ,Viral disease ,Complication ,business - Abstract
Five patients with lymphoproliferative malignancies and chronic hepatitis B suffered severe acute hepatic injury after the withdrawal of multiagent chemotherapy that included high-dose corticosteroid. Four patients died of hepatic failure, three of whom received corticosteroid as treatment for the hepatic injury. We believe that the cause of this entity is massive immune-associated cytolysis of hepatitis B virus infected hepatocytes occurring after a period of immunosuppression and increased viral replication. The literature regarding this complication of chemotherapy and its pathophysiology is reviewed.
- Published
- 1990
6. Malignant peripheral nerve sheath tumor arising in an adrenal ganglioneuroma in an adult male homosexual
- Author
-
Para Chandrasoma, Randall Radin, Michael Koss, Darryl Shibata, and Lauren Pinter Brown
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Neurofibroma ,Adult male ,business.industry ,Adrenal Gland Neoplasms ,Ganglioneuroma ,Malignant peripheral nerve sheath tumor ,Homosexuality ,medicine.disease ,Metastasis ,Neoplasms, Multiple Primary ,Oncology ,Peripheral Nervous System Neoplasms ,Neuroblastoma ,medicine ,Humans ,Neoplasm ,Neoplasm Recurrence, Local ,business ,Lymphatic Diseases - Abstract
The authors report a case of malignant peripheral nerve sheath tumor arising in an adrenal ganglioneuroma in an adult. This is the first such case occurring in the absence of a history of childhood neuroblastoma treated with radiation, and provides evidence that such a transformation can occur spontaneously. The neoplasm demonstrated a highly malignant biologic behavior with rapid growth, local recurrence, and metastasis.
- Published
- 1986
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.